{"id":301784,"date":"2026-10-12T12:10:19","date_gmt":"2026-10-12T06:40:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=301784"},"modified":"2026-10-12T12:10:19","modified_gmt":"2026-10-12T06:40:19","slug":"trusted-medicine-brand-stocks-future-growth-watchlist","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/","title":{"rendered":"3 Trusted Medicine Brand Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Mankind Pharma and FDC"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>GSK Pharma Rs 2,540.30, P\/E 40.20. Mankind Pharma Rs 2,368.50, P\/E 47.91. FDC Rs 330.15, P\/E 18.05. Closing prices of 9 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Trusted medicine brand stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines, Mankind Pharma in chronic and acute branded formulations and FDC in oral rehydration and ophthalmic products. FY26 revenue growth was 1.8% at GSK Pharma, 14.8% at Mankind Pharma and 3.9% at FDC. P\/E stands at 40.20 for GSK Pharma (industry 37.59), 47.91 for Mankind Pharma (industry 37.59) and 18.05 for FDC (industry 37.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company&#8217;s risks need equal attention.<\/p>\n<\/p><\/div>\n<p>Trusted medicine brand stocks give investors exposure to medicines and health products that doctors and patients ask for by name. Prescription volumes, brand strength and margins decide how much of that trust turns into profit.<\/p>\n<p>This list covers three trusted medicine brand stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines, Mankind Pharma for chronic and acute branded formulations and FDC for oral rehydration and ophthalmic products. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=trusted-medicine-brand-stocks-future-growth-watchlist\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#What_Are_Trusted_Medicine_Brand_Stocks\" title=\"What Are Trusted Medicine Brand Stocks?\">What Are Trusted Medicine Brand Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Trusted_Medicine_Brand_Stocks_at_a_Glance\" title=\"Trusted Medicine Brand Stocks at a Glance\">Trusted Medicine Brand Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Why_Do_Trusted_Medicine_Brand_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Trusted Medicine Brand Stocks Have a Strong Roadmap in India?\">Why Do Trusted Medicine Brand Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#GlaxoSmithKline_Pharmaceuticals_Branded_Medicines_and_Vaccines_Anchor_the_Roadmap\" title=\"GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap\">GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Mankind_Pharma_Branded_Formulations_Anchor_the_Roadmap\" title=\"Mankind Pharma: Branded Formulations Anchor the Roadmap\">Mankind Pharma: Branded Formulations Anchor the Roadmap<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#FDC_Established_Brands_Drive_the_Pipeline\" title=\"FDC: Established Brands Drive the Pipeline\">FDC: Established Brands Drive the Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Best_Trusted_Medicine_Brand_Stocks_in_India_GSK_Pharma_vs_Mankind_Pharma_vs_FDC_on_Key_Financials\" title=\"Best Trusted Medicine Brand Stocks in India: GSK Pharma vs Mankind Pharma vs FDC on Key Financials\">Best Trusted Medicine Brand Stocks in India: GSK Pharma vs Mankind Pharma vs FDC on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#How_to_Evaluate_Trusted_Medicine_Brand_Stocks_to_Buy_Before_You_Invest\" title=\"How to Evaluate Trusted Medicine Brand Stocks to Buy Before You Invest\">How to Evaluate Trusted Medicine Brand Stocks to Buy Before You Invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Risks_to_Consider_Before_Investing_in_Trusted_Medicine_Brand_Stocks\" title=\"Risks to Consider Before Investing in Trusted Medicine Brand Stocks\">Risks to Consider Before Investing in Trusted Medicine Brand Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Final_Take_Which_Stock_Has_the_Strongest_Roadmap\" title=\"Final Take: Which Stock Has the Strongest Roadmap?\">Final Take: Which Stock Has the Strongest Roadmap?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#FAQs_on_Trusted_Medicine_Brand_Stocks\" title=\"FAQs on Trusted Medicine Brand Stocks\">FAQs on Trusted Medicine Brand Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Which_are_the_best_trusted_medicine_brand_stocks_in_India_with_a_strong_roadmap\" title=\"Which are the best trusted medicine brand stocks in India with a strong roadmap?\">Which are the best trusted medicine brand stocks in India with a strong roadmap?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Is_GlaxoSmithKline_Pharmaceuticals_a_good_stock_to_buy_now\" title=\"Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?\">Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#What_is_the_PE_ratio_of_GSK_Pharma_Mankind_Pharma_and_FDC\" title=\"What is the P\/E ratio of GSK Pharma, Mankind Pharma and FDC?\">What is the P\/E ratio of GSK Pharma, Mankind Pharma and FDC?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Which_of_these_trusted_medicine_brand_stocks_has_the_highest_return_on_equity\" title=\"Which of these trusted medicine brand stocks has the highest return on equity?\">Which of these trusted medicine brand stocks has the highest return on equity?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#What_are_the_risks_of_investing_in_trusted_medicine_brand_stocks\" title=\"What are the risks of investing in trusted medicine brand stocks?\">What are the risks of investing in trusted medicine brand stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#How_did_GSK_Pharma_Mankind_Pharma_and_FDC_perform_in_Q1_FY27\" title=\"How did GSK Pharma, Mankind Pharma and FDC perform in Q1 FY27?\">How did GSK Pharma, Mankind Pharma and FDC perform in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#Do_trusted_medicine_brand_stocks_pay_dividends\" title=\"Do trusted medicine brand stocks pay dividends?\">Do trusted medicine brand stocks pay dividends?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/trusted-medicine-brand-stocks-future-growth-watchlist\/#How_can_I_invest_in_trusted_medicine_brand_stocks_in_India\" title=\"How can I invest in trusted medicine brand stocks in India?\">How can I invest in trusted medicine brand stocks in India?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Trusted_Medicine_Brand_Stocks\"><\/span><strong>What Are Trusted Medicine Brand Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Trusted medicine brand stocks are shares of companies that make and sell branded medicines and health products. Results depend on prescription volumes, brand strength and margins, so margins and brand strength separate the stronger names.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Trusted_Medicine_Brand_Stocks_at_a_Glance\"><\/span><strong>Trusted Medicine Brand Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares size, valuation, return on equity and debt for the three trusted medicine brand stocks as of the 9 Oct 2026 close.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Debt to Equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/glaxo\/glaxosmithkline-pharmaceuticals-ltd-share-price-today\">GlaxoSmithKline Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,540.30<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">42,939<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">40.20<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.59<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45.69%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,368.50<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">99,065<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">47.91<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.59<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.74%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.39<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/fdc\/fdc-ltd-share-price-today\">FDC<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">330.15<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,281<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.05<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.59<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.32%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p>Among branded medicine stocks, GSK Pharma and Mankind Pharma trade at a premium to the industry P\/E, while FDC trades at a discount.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Trusted_Medicine_Brand_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Trusted Medicine Brand Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Trusted medicine brand stocks have a strong roadmap in India because doctor-prescribed brands earn repeat demand, and rising health spending keeps volumes growing. Three drivers stand out.<\/p>\n<ul>\n<li><strong>Brand trust:<\/strong> Patients stay with medicines they know.<\/li>\n<li><strong>Doctor reach:<\/strong> Large field forces keep brands on prescription pads.<\/li>\n<li><strong>Health spending:<\/strong> Rising incomes and insurance widen the market.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"GlaxoSmithKline_Pharmaceuticals_Branded_Medicines_and_Vaccines_Anchor_the_Roadmap\"><\/span><strong>GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>GSK Pharma&#8217;s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.<\/p>\n<p>Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.<\/p>\n<p>Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P\/E of 40.20 against an industry P\/E of 37.59, the stock trades above its industry multiple.<\/p>\n<p>What to watch: The P\/E of 40.20 is a modest premium to the industry P\/E of 37.59, so the next quarters&#8217; growth is the figure to follow.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Branded_Formulations_Anchor_the_Roadmap\"><\/span><strong>Mankind Pharma: Branded Formulations Anchor the Roadmap<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mankind Pharma&#8217;s roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.<\/p>\n<p>Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.<\/p>\n<p>Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P\/E of 47.91 against an industry P\/E of 37.59, the stock trades above its industry multiple.<\/p>\n<p>What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FDC_Established_Brands_Drive_the_Pipeline\"><\/span><strong>FDC: Established Brands Drive the Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>FDC&#8217;s roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.<\/p>\n<p>Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.<\/p>\n<p>Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P\/E of 18.05 against an industry P\/E of 37.59, the stock trades below its industry multiple.<\/p>\n<p>What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Best_Trusted_Medicine_Brand_Stocks_in_India_GSK_Pharma_vs_Mankind_Pharma_vs_FDC_on_Key_Financials\"><\/span><strong>Best Trusted Medicine Brand Stocks in India: GSK Pharma vs Mankind Pharma vs FDC on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the best trusted medicine brand stocks in India, GSK Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Mankind Pharma leads on FY26 revenue growth and Q1 FY27 net profit growth; FDC leads on the lowest P\/E. The table puts the numbers side by side.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Metric<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">GSK Pharma<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Mankind Pharma<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FDC<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">FY26 revenue (Rs Cr)<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,967.03<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,636.43<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,284.45<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">FY26 revenue growth<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">FY26 net profit (Rs Cr)<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,035.98<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,938.10<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">281.42<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">FY26 operating profit margin<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.60%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.06%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.21%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Q1 FY27 revenue growth (YoY)<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Q1 FY27 net profit growth (YoY)<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Return on equity<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">45.69%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.74%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.32%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">P\/E ratio<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">40.20<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">47.91<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.05<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Debt to equity<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.39<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dividend yield<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2.25%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.04%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.54%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">FY26 operating cash flow (Rs Cr)<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">903.30<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,121.29<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">200.45<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p>Pharma earnings follow prescription volumes, brand strength and margins, so full-year numbers and quarterly trends together give a better view.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Evaluate_Trusted_Medicine_Brand_Stocks_to_Buy_Before_You_Invest\"><\/span><strong>How to Evaluate Trusted Medicine Brand Stocks to Buy Before You Invest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A short checklist keeps the research consistent when you screen trusted medicine brand stocks and shortlist trusted medicine brand stocks to buy.<\/p>\n<ol>\n<li>Compare each stock&#8217;s P\/E with its industry P\/E, which is 37.59 for all three here.<\/li>\n<li>Check margins and return on equity to see how well the brands convert into profit.<\/li>\n<li>Check whether revenue growth is turning into profit growth, not only sales.<\/li>\n<li>Read operating cash flow against capital expenditure to see how growth is funded.<\/li>\n<li>Watch debt to equity and interest cover before sizing a position.<\/li>\n<li>Spread exposure across companies and business lines instead of one demand cycle.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these trusted medicine brand stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Consider_Before_Investing_in_Trusted_Medicine_Brand_Stocks\"><\/span><strong>Risks to Consider Before Investing in Trusted Medicine Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Price controls:<\/strong> Government limits on drug prices can reduce margins.<\/li>\n<li><strong>Competition:<\/strong> Generic and new brands compete for the same prescriptions.<\/li>\n<li><strong>Quarterly trends:<\/strong> A single weak quarter can change near-term earnings, so track results every quarter.<\/li>\n<\/ul>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track GSK Pharma, Mankind Pharma and FDC live.<\/em><\/p>\n<p>Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.<\/p>\n<p>Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.<\/p>\n<p>The shareholding pattern published every quarter shows whether promoters, mutual funds and foreign investors are raising or trimming their holdings, which adds useful context to the financial numbers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Take_Which_Stock_Has_the_Strongest_Roadmap\"><\/span><strong>Final Take: Which Stock Has the Strongest Roadmap?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>These three branded medicine stocks cover branded medicines, vaccines and household health products. GSK Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Mankind Pharma leads on FY26 revenue growth and Q1 FY27 net profit growth; FDC leads on the lowest P\/E.<\/p>\n<p>Across trusted medicine brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the trusted medicine brand stocks to buy discussed here.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Trusted_Medicine_Brand_Stocks\"><\/span><strong>FAQs on Trusted Medicine Brand Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_trusted_medicine_brand_stocks_in_India_with_a_strong_roadmap\"><\/span><strong>Which are the best trusted medicine brand stocks in India with a strong roadmap?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> GlaxoSmithKline Pharmaceuticals, Mankind Pharma and FDC stand out for their roadmaps in branded medicines, vaccines and household health products. FY26 revenue growth was 1.8% at GSK Pharma, 14.8% at Mankind Pharma and 3.9% at FDC, and return on equity ranges from 11.32% to 45.69%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_GlaxoSmithKline_Pharmaceuticals_a_good_stock_to_buy_now\"><\/span><strong>Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P\/E of 40.20 against an industry P\/E of 37.59. Valuation, price controls and competition move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_GSK_Pharma_Mankind_Pharma_and_FDC\"><\/span><strong>What is the P\/E ratio of GSK Pharma, Mankind Pharma and FDC?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The P\/E ratio is 40.20 for GSK Pharma (industry 37.59), 47.91 for Mankind Pharma (industry 37.59) and 18.05 for FDC (industry 37.59). Only GSK Pharma and Mankind Pharma trade at or above the industry multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_trusted_medicine_brand_stocks_has_the_highest_return_on_equity\"><\/span><strong>Which of these trusted medicine brand stocks has the highest return on equity?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Mankind Pharma at 11.74% and FDC at 11.32%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_trusted_medicine_brand_stocks\"><\/span><strong>What are the risks of investing in trusted medicine brand stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are price controls, competition and quarterly trends. Government limits on drug prices can reduce margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_GSK_Pharma_Mankind_Pharma_and_FDC_perform_in_Q1_FY27\"><\/span><strong>How did GSK Pharma, Mankind Pharma and FDC perform in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Do_trusted_medicine_brand_stocks_pay_dividends\"><\/span><strong>Do trusted medicine brand stocks pay dividends?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, all three companies pay dividends. The dividend yield is 2.25% for GSK Pharma, 0.04% for Mankind Pharma and 1.54% for FDC, based on dividends declared for FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_invest_in_trusted_medicine_brand_stocks_in_India\"><\/span><strong>How can I invest in trusted medicine brand stocks in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy trusted medicine brand stocks through a demat and trading account on NSE or BSE after checking each company&#8217;s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best trusted medicine brand stocks in India with a strong roadmap?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"GlaxoSmithKline Pharmaceuticals, Mankind Pharma and FDC stand out for their roadmaps in branded medicines, vaccines and household health products. FY26 revenue growth was 1.8% at GSK Pharma, 14.8% at Mankind Pharma and 3.9% at FDC, and return on equity ranges from 11.32% to 45.69%.\"}},{\"@type\":\"Question\",\"name\":\"Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P\/E of 40.20 against an industry P\/E of 37.59. Valuation, price controls and competition move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.\"}},{\"@type\":\"Question\",\"name\":\"What is the P\/E ratio of GSK Pharma, Mankind Pharma and FDC?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E ratio is 40.20 for GSK Pharma (industry 37.59), 47.91 for Mankind Pharma (industry 37.59) and 18.05 for FDC (industry 37.59). Only GSK Pharma and Mankind Pharma trade at or above the industry multiple.\"}},{\"@type\":\"Question\",\"name\":\"Which of these trusted medicine brand stocks has the highest return on equity?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Mankind Pharma at 11.74% and FDC at 11.32%.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in trusted medicine brand stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are price controls, competition and quarterly trends. Government limits on drug prices can reduce margins.\"}},{\"@type\":\"Question\",\"name\":\"How did GSK Pharma, Mankind Pharma and FDC perform in Q1 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore.\"}},{\"@type\":\"Question\",\"name\":\"Do trusted medicine brand stocks pay dividends?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, all three companies pay dividends. The dividend yield is 2.25% for GSK Pharma, 0.04% for Mankind Pharma and 1.54% for FDC, based on dividends declared for FY26.\"}},{\"@type\":\"Question\",\"name\":\"How can I invest in trusted medicine brand stocks in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"You can buy trusted medicine brand stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline Pharmaceuticals, Mankind Pharma and FDC compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.<\/p>\n","protected":false},"author":34,"featured_media":301783,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[11207,11206,805,11204,11205],"class_list":["post-301784","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-fdc","tag-glaxosmithkline-pharmaceuticals","tag-mankind-pharma","tag-trusted-medicine-brand-stocks","tag-trusted-medicine-brand-stocks-to-buy"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["301783"],"rank_math_title":["Trusted Medicine Brand Stocks: Top 3 Roadmap Picks"],"rank_math_description":["Trusted medicine brand stocks with a strong roadmap: GSK Pharma, Mankind Pharma and FDC compared on growth, margins, valuation and risks."],"rank_math_focus_keyword":["trusted medicine brand stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-trusted-medicine-brand-stocks-with-a-strong-future-roadmap-glaxosmithkline.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/301784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=301784"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/301784\/revisions"}],"predecessor-version":[{"id":301785,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/301784\/revisions\/301785"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/301783"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=301784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=301784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=301784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}